Arachidonic Acid

Arachidonic Acid

SCHEMBL3064936

CCCCCC=CCC=CCC=CCC=CCCCC(=O)O.OO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 1.00
PPARD Q03181 6/20 1.00
PPARA Q07869 6/20 1.00
ALDH1A1 P00352 5/20 1.00
FABP4 P15090 4/20 1.00
HSD17B10 Q99714 4/20 1.00
LMNA P02545 3/20 1.00
CYP19A1 P11511 3/20 1.00
ALOX15 P16050 3/20 1.00
NR4A2 P43354 3/20 1.00
MAPT P10636 3/20 1.00
BLM P54132 3/20 1.00
L3MBTL1 Q9Y468 2/20 1.00
KDM4E B2RXH2 2/20 1.00
CYP3A4 P08684 2/20 1.00
HPGD P15428 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
AKR1C3 P42330 2/20 1.00
USP2 O75604 2/20 1.00
RECQL P46063 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7875988 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL18185463 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
SCHEMBL7875990 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
SCHEMBL17540736 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
SCHEMBL542242 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
SCHEMBL13033028 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL25417373 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL18185503 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL607755 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL20656587 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119559-A1 Topically active agents to remove actinic keratoses and basal (BCC) and squamous (SCC) cell carcinomas using a combination of sulindac, its metabolites and derivatives with an oxidizing agent to generate reactive oxygen species nontoxic to normal cells; sulindac methionine sulfoxide/hydrogen peroxide FLORIDA ATLANTIC UNIVERSITY (US) 2008-05-22 US claimed
EP-1865972-A2 TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS FLORIDA ATLANTIC UNIVERSITY (US) 2007-12-19 EP claimed
US-20060235080-A1 Treatment or prevention of cancer and precancerous disorders FLORIDA ATLANTIC UNIVERSITY (US) 2006-10-19 US claimed
WO-2006102439-A2 TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS FLORIDA ATLANTIC UNIVERSITY (US) 2006-09-28 WO claimed
WO-2000044931-A2 HIGH-THROUGHPUT SCREENING ASSAYS FOR MODULATORS OF ATPASE BION, INC. (US) 2000-08-03 WO claimed
US-4657856-A FERMENTATION OF MUCOR, BLOCKING AGENTS, FLUORESCENT REAGENT KYOWA HAKKO KOGYO CO., LTD. (JP) 1987-04-14 US claimed
EP-0049078-B1 GLUTATHIONE PEROXIDASE, PROCESS FOR PRODUCTION THEREOF, METHOD AND COMPOSITION FOR THE QUANTITATIVE DETERMINATION OF LIPID PEROXIDE KYOWA HAKKO KOGYO CO., LTD. (JP) 1986-04-30 EP claimed
EP-0049078-A2 Glutathione peroxidase, process for production thereof, method and composition for the quantitative determination of lipid peroxide KYOWA HAKKO KOGYO CO., LTD. (JP) 1982-04-07 EP claimed
US-20210041467-A1 METHODS FOR ASSESSING THE NEED FOR AND THE EFFECTIVENESS OF THERAPY WITH ANTIOXIDANTS THE PROIMMUNE COMPANY, LLC 2021-02-11 US disclosed
US-20200141956-A1 METHODS OF ASSESSING THE NEED FOR AND THE EFFECTIVENESS OF THERAPY WITH ANTIOXIDANTS THE PROIMMUNE COMPANY, LLC 2020-05-07 US disclosed
US-20160341748-A1 Methods of assessing the need for and the effectiveness of therapy with antioxidants CRUM ALBERT B (US) 2016-11-24 US disclosed
US-9229014-B2 Methods of assessing the need for and the effectiveness of therapy with antioxidants THE PROIMMUNE COMPANY, LLC 2016-01-05 US disclosed
US-8765808-B2 Treatment or prevention of cancer and precancerous disorders CHS PHARMA, INC. (US) 2014-07-01 US disclosed
US-8603985-B2 Treatment or prevention of cancer and precancerous disorders CHS Pharma, Inc (US) 2013-12-10 US disclosed
US-4900680-A Method and apparatus for measuring lipid peroxide TOHOKU ELECTRONIC INDUSTRIAL CO., LTD. (JP) 1990-02-13 US disclosed
US-4657856-A FERMENTATION OF MUCOR, BLOCKING AGENTS, FLUORESCENT REAGENT KYOWA HAKKO KOGYO CO., LTD. (JP) 1987-04-14 US disclosed
EP-0049078-B1 GLUTATHIONE PEROXIDASE, PROCESS FOR PRODUCTION THEREOF, METHOD AND COMPOSITION FOR THE QUANTITATIVE DETERMINATION OF LIPID PEROXIDE KYOWA HAKKO KOGYO CO., LTD. (JP) 1986-04-30 EP disclosed
US-4464304-A Vinyl Cyclopropyl compounds as precursors to fatty acid oxidation products DUKE UNIVERSITY (US) 1984-08-07 US disclosed
US-4350834-A Vinyl cyclopropyl compounds as precursors to fatty acid oxidation products DUKE UNIVERSITY (US) 1982-09-21 US disclosed
EP-0049078-A2 Glutathione peroxidase, process for production thereof, method and composition for the quantitative determination of lipid peroxide KYOWA HAKKO KOGYO CO., LTD. (JP) 1982-04-07 EP disclosed